DOI QR코드

DOI QR Code

Evaluation of the prevalence and clinical impact of toxocariasis in patients with eosinophilia of unknown origin

  • Kim, Hong-Beum (Department of Natural Medical Sciences, Chosun University College of Health Science) ;
  • Seo, Jun-Won (Department of Internal Medicine, Chosun University Hospital) ;
  • Lee, Jun-Hyung (Department of Internal Medicine, Chosun University Hospital) ;
  • Choi, Byung-Seok (Department of Medicine, Chosun University Graduate School of Medicine) ;
  • Park, Sang-Gon (Department of Internal Medicine, Chosun University Hospital)
  • 투고 : 2014.09.05
  • 심사 : 2015.06.15
  • 발행 : 2017.05.01

초록

Background/Aims: Eosinophilia has numerous diverse causes, and in many patients, it is not possible to establish the cause of eosinophilia. Recently, toxocariasis was introduced as one cause of eosinophilia. The aims of this study were to evaluate the prevalence of toxocariasis and the clinical impact of albendazole treatment for toxocariasis in patients suspected of eosinophilia of unknown origin. Methods: We performed a retrospective chart review. After evaluation of cause of eosinophilia, the patients suspected of eosinophilia of unknown origin performed immunoglobulin G antibody specific assay for the Toxocara canis larval antigen by enzyme-linked immunosorbent assay. Results: This study evaluated 113 patients, 69 patients (61%) were suspected of eosinophilia of unknown origin. Among these 69 patients, the frequency of T. canis infection was very high (45 patients, 65.2%), and albendazole treatment for 45 eosinophilia with toxocariasis was highly effective for a cure of eosinophilia than no albendazole group regardless of steroid (82.3%, p = 0.007). Furthermore, among the nonsteroid treated small group (19 patients), albendazole treatment for eosinophilia were more effective than no albendazole group, too (83.3% vs. 28.6 %, p = 0.045). Conclusions: The prevalence of toxocariasis was high among patients suspected of eosinophilia of unknown origin; therefore, evaluation for T. canis infection is recommended for patients with eosinophilia of unknown origin. Furthermore, for patients suspected of eosinophilia of unknown origin who have positive results for T. canis, albendazole treatment may be considered a valuable treatment option.

키워드

참고문헌

  1. Akao N, Ohta N. Toxocariasis in Japan. Parasitol Int 2007;56:87-93. https://doi.org/10.1016/j.parint.2007.01.009
  2. Morris PD, Katerndahl DA. Human toxocariasis: review with report of a probable case. Postgrad Med 1987;81:263-267.
  3. Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. Clin Microbiol Rev 2003;16:265-272. https://doi.org/10.1128/CMR.16.2.265-272.2003
  4. Johkoh T, Muller NL, Akira M, et al. Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients. Radiology 2000;216:773-780. https://doi.org/10.1148/radiology.216.3.r00se01773
  5. Obwaller A, Jensen-Jarolim E, Auer H, Huber A, Kraft D, Aspock H. Toxocara infestations in humans: symptomatic course of toxocarosis correlates significantly with levels of IgE/anti-IgE immune complexes. Parasite Immunol 1998;20:311-317. https://doi.org/10.1046/j.1365-3024.1998.00146.x
  6. Kwon NH, Oh MJ, Lee SP, Lee BJ, Choi DC. The prevalence and diagnostic value of toxocariasis in unknown eosinophilia. Ann Hematol 2006;85:233-238. https://doi.org/10.1007/s00277-005-0069-x
  7. Arias Irigoyen J, Senent Sanchez CJ. Toxocariasis: a cause of hyper IgE and eosinophilia. J Investig Allergol Clin Immunol 1995;5:232-234.
  8. van Assendelft OW. Reference values for the total and differential leukocyte count. Blood Cells 1985;11:77-96.
  9. Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol 2010;126:39-44. https://doi.org/10.1016/j.jaci.2010.04.011
  10. Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003;121:203-223. https://doi.org/10.1046/j.1365-2141.2003.04195.x
  11. Roldan W, Cornejo W, Espinoza Y. Evaluation of the dot enzyme-linked immunosorbent assay in comparison with standard ELISA for the immunodiagnosis of human toxocariasis. Mem Inst Oswaldo Cruz 2006;101:71-74. https://doi.org/10.1590/S0074-02762006000100013
  12. Kim DW, Shin MG, Yun HK, et al. Incidence and causes of hypereosinophilia (corrected) in the patients of a university hospital. Korean J Lab Med 2009;29:185-193. https://doi.org/10.3343/kjlm.2009.29.3.185
  13. Lim JH, Lee KS. Eosinophilic infiltration in Korea: idiopathic? Korean J Radiol 2006;7:4-6. https://doi.org/10.3348/kjr.2006.7.1.4
  14. Pawlowski Z. Toxocariasis in humans: clinical expression and treatment dilemma. J Helminthol 2001;75:299-305. https://doi.org/10.1017/S0022149X01000464
  15. Kim YH, Huh S, Chung YB. Seroprevalence of toxocariasis among healthy people with eosinophilia. Korean J Parasitol 2008;46:29-32. https://doi.org/10.3347/kjp.2008.46.1.29
  16. Magnaval JF, Michault A, Calon N, Charlet JP. Epidemiology of human toxocariasis in La Reunion. Trans R Soc Trop Med Hyg 1994;88:531-533. https://doi.org/10.1016/0035-9203(94)90148-1
  17. Malla N, Aggarwal AK, Mahajan RC. A serological study of human toxocariasis in north India. Natl Med J India 2002;15:145-147.
  18. Logar J, Soba B, Kraut A, Stirn-Kranjc B. Seroprevalence of Toxocara antibodies among patients suspected of ocular toxocariasis in Slovenia. Korean J Parasitol 2004;42:137-140. https://doi.org/10.3347/kjp.2004.42.3.137
  19. Stensvold CR, Skov J, Moller LN, et al. Seroprevalence of human toxocariasis in Denmark. Clin Vaccine Immunol 2009;16:1372-1373. https://doi.org/10.1128/CVI.00234-09
  20. Yoon YS, Lee CH, Kang YA, et al. Impact of toxocariasis in patients with unexplained patchy pulmonary infiltrate in Korea. J Korean Med Sci 2009;24:40-45. https://doi.org/10.3346/jkms.2009.24.1.40

피인용 문헌

  1. TOXOCARÍASE MIMETIZANDO SÍNDROME DE SJOGREN: RELATO DE CASO vol.57, pp.suppl1, 2017, https://doi.org/10.1016/j.rbr.2017.06.116
  2. Diagnostic Approach to Peripheral Eosinophilia vol.92, pp.4, 2017, https://doi.org/10.3904/kjm.2017.92.4.382
  3. First Report of Toxocara canis Seroprevalence in Military Personnel and Their Families with Eosinophilia Referred to a Military Hospital in Tehran, Iran, 2015 - 2016 vol.13, pp.2, 2017, https://doi.org/10.5812/archcid.57785
  4. Toxocara canis Mimicking a Metastatic Omental Mass from Sigmoid Colon Cancer: A Case Report vol.34, pp.3, 2018, https://doi.org/10.3393/ac.2017.12.20
  5. Clinical course and treatment outcomes of toxocariasis-related eosinophilic disorder vol.97, pp.37, 2017, https://doi.org/10.1097/md.0000000000012361
  6. Toxocara vitulorum cuticle glycoproteins in the diagnosis of calves’ toxocariasis vol.12, pp.2, 2017, https://doi.org/10.14202/vetworld.2019.288-294
  7. A clinical case of visceral toxocariasis as a cause of eosinophilic polyserositis vol.91, pp.11, 2017, https://doi.org/10.26442/00403660.2019.11.000314
  8. Electrochemical detection of Toxocara canis excretory-secretory antigens in children from rural communities in Esmeraldas Province, Ecuador: association between active infection and high eosinophili vol.13, pp.1, 2017, https://doi.org/10.1186/s13071-020-04113-2
  9. The role of peripheral eosinophilia in diagnosing lung disorders: experience from a single pneumonological center vol.16, pp.None, 2021, https://doi.org/10.4081/mrm.2021.770
  10. The kinetic profile of clinical and laboratory findings and treatment outcome of patients with toxocariasis vol.26, pp.11, 2017, https://doi.org/10.1111/tmi.13665
  11. The Framework for Human Host Immune Responses to Four Types of Parasitic Infections and Relevant Key JAK/STAT Signaling vol.22, pp.24, 2017, https://doi.org/10.3390/ijms222413310